SlideShare a Scribd company logo
1 of 57
PREGNANCY WITH CONVULSIONS
AND COMA- RARE BUT DREADED
DISASTERS
Convulsions in pregnancy
Convulsions due to pregnancy
Eclampsia
Convulsions aggravated by
Pregnancy Epilepsy
Convulsions in pregnancy
Convulsions not Directly related to pregnancy
Infections
Meningitis
Encephalitis
Cerebral Malaria
Cerebral Absces
Febrile convulsions
Cerebrovascular
Accidents
Venous Thrombosis
Infarction
Haemorrhage
Metabolic/Electolyte imbalance
Hypoglycemia
Hyperglycemia
Hyponatremia
Hypocalcemia
Trauma Tetany
Drug Withdrawal Cocaine
Alcohol
Psychiatric disorders
ECLAMPSIA
New-onset convulsionsafter 20wks of pregnancy in
a patient with Preeclampsia (PIH) with no
coincidental neurologic disease, is called
Eclampsia.
Eclampsia
The incidence of eclampsia in the developed countries is 1:2000
deliveries. while in developing countries estimate vary widely,
from 1 in 100 to 1 in 1700 deliveries .
ANTEPARTUM (50%)
INTRAPARTUM (30%).
POSTPARTUM (20%) within 48hrs-upto 7days.
INTERCURRENT (Rare) – Pt becomes conscious after recovery
from convulsion and pregnancy continues beyond 48hrs.
Convulsions in Pregnancy
Differential Diagnosis
Eclampsia
History
Occurs after 20wks of
preg
H/o PIH in this
Pregnancy
Prev H/o Eclampsia +/-
H/o Tonic Clonic
convulsion
Clinical Exam
H/o Hypertension,
Proteinuria,Edema,Oliguri
a,p ulmonary Edema
Epilepsy
Occur anytime during preg
H/o Prev Epileptic fits
Fits may be Recurrent
Fits Generalised/Focal
No H/o
Hypertension,Proteinuria,
Edema
Convulsion in Pregnancy
Differential Diagnosis
Investigations
Eclampsia
Complete bloodcount
Haematocrit
Plateletcount
 Coagulation profile
 Serum creatinine
Serum uric acid
Liver function tests
Complete urine
examination
Fundoscopy
Epilepsy
EEG
Cerebral Imaging (MRI)
Maternal Complications of Eclampsia
Injuries –Tongue bite
Pulmonary Edema.
Aspiration Pneumonia(2%-
5%)
Long Term Cardiovascular
Morbidity
Abruptio- Placentae (1%-4%)
Disseminated Coagulopathy.
HELLP Syndrome (3-4%)
Acute Renal Failure (1%-5%)
Liver Failure OR Haemorrhage
(<1%)
Cerebral haemorrhage
Postpartum collapse
Blindness
Death (Rare)
Complications
 IUGR(10-25%)
Hypoxia- Neurologic Injury (<1%)
Perinatal Death (1%-2%)
Long Term Cardiovascular Morbidity Associated
with Low Birth Weight
AIMS OF MANAGEMENT OF ECLAMPSIA
Control convulsions, prevent cerebro-vascular
accident and COMA
Stabilise blood pressure
Optimise patient
Deliver fetus
19/10/2014 11
Management of eclampsia
Teamapproach
O&G specialist
Anesthesiologist
 Paediatrician
Physician
Nursing Staff
Blood bank personnel
GENERAL MANAGEMENT OF ECLAMPSIA
position patient to herside in railed cot
Mouth gag placed between theteeth
clearairway secretions
maintain oxygenation 15 LIT/ MIN
set up intravenousaccess
Put self retaining catheter
monitor vital signs - BP, PR, respiration1/2hrly
if diastolic BP > 110mmHg, considerantihypertensive
monitor fetal heart rate forgestations > 28 weeks
Antibiotic
13
Anticonvulsant Therapy
Magnesiumsulphate (MgSO4)
Diazepam
Phenytoin
MgSO4 Mechanism ofaction
Slowed neuromuscular conduction & decreased CNS
irritability
Cerebral vasodilatation
Increased production of endothelial prostacycline and
inhibition of platelet activation
Protection of endothelial cells from injury mediated by free
radicals
Dilatation of uterine arteries
MgSo4 as anticonvulsant
Prichard’s regimen (IM)
Loading Dose-
4gm (20%) slow IV over
3-5mt f/b 10gm (50%) deep IM
(5gm in each
buttock)
Maintenance Dose-
5gm (50%) IM 4hrly in alternate
buttock
Zuspan regimen (IV)
Loading Dose-4-6gm slow IV in
100ml 5% Dextrose over 15-20 mt
F/b 5gm IV in 5%Dextrose(1gm/hr
IV infusion)
Monitoring of patient on magnesium
sulphate
Therapeutic levels (if available)
 Serum magnesium levels between 4.0-7.0 mEq/L
Patellar reflex Present
(Lost at serum Mg Levels of 8 – 10 mEq/L Urine
Output >30 ml/ hr
Every hour Respiratory rate > 12/min
every 15 mins
Respiratory depression (serum Mg level
>10
mEq/L)
Respiratory arrest (serum Mg level > 12 mEq/L)
19/10/2014 17

Managing Magnesium Toxicity
 Respiratory depression
 Stop magnesiumtherapy
 Oxygen
 IVcalciumgluconate 10% 10ml IV slow bolus
 Maintainairway
 Respiratory arrest
 Stop magnesiumtherapy
 IVcalciumgluconate 10% 10 ml IV slow bolus
 Tracheal Intubation andventilation
19/10/2014 18
Effects of Mg sulphate on thenewborn
MgSO4 crosses the placentafreely
Minimal side effects if maternal serum
levels are maintained
Hyporeflexia and Respiratory depression
Lethargy
19
- Anticonvulsant therapy
Diazepam
 Useful for status seizures
 dosage – 10 -20 mg iv at a rate of 5 mg per min
 may be repeated at 10 to 15 minute intervals
 Maintainence – 40mg in 500ml of 5% Dextrose IV infusion,to
keep patient sedated
Side effects - loss of consciousness, hypotension,
respiratory depression
Caution - may increase risk of aspiration
causes prolonged depression of the neonate
Phenytoin
 Centrally acting anticonvulsant
Dose ( with ECG monitoring )
10mg/Kg I/V (not more than50mg/mt) F/b
5mg/Kg I/V after 2hr
12 hr. — 500mg I/V
200mg 8hrly. X 5 days
SE- Hypotension, Cardiac dysrhythmia & Phlebitis
Fluid replacement
Should not exceed 1-2 ml/kg/hour or 85 ml/hour
whichever is lower
Crystalloid Solution (RL)
Total Fluid =24hr urine +1000ml
Maintain a urine output of more than 30 ml/hour
CVP should not exceed 7 cm of H2O
When patient is taking oral fluids, the amount
taken should be subtracted from the amount
infused
22
Anti hypertensive management
Objective is to prevent maternal cerebrovascular
accidents
Hydralazine
 5mg -10mg I/V at 15 – 20 mts. Interval till control is achieved.
Maximum dose 15mg – 20mg
Labetelol
 Start with 200mg/100ml IV at 20mg/hr. I/v. Double the dose
every 30 min. till control is achieved or a dose of 160mg/hr. is
reached
 Nifedipine
 5mmg – 10mg S/L every 15 – 30 minutes until BP is contolled A
maximum 180mg can be used in a day
Treatment of complications of Eclampsia
If pulmonary oedema develops, give intravenous
Frusemide 40mg, oxygen and manage patient in the ICU
If oliguria develops or when urine output is less than
30ml/hour for 4 hours – challenge with 200 mls of
crystalloid over 5 minutes . Evaluate over a 4 hour
period
If oliguria persists despite a CVP of between 7 – 10 cm H2O
– refer to Nephrologist for further management.
Hyperpyrexia- Cold sponging , Antipyretics
Heart failure-O2 inhalation, IV Lasix, & Digitalis
24
Obstetrical management of eclampsia
treatment
The Definitive
Is Delivery
19/10/2014 25
Indications of LSCS IN
Eclampsia
Uncontrolled fits in spite oftherapy
Poor prospects for vaginalDelivery
Worsening maternal diseaseprocess
Uncontrolled hypertension (>180/120mm Hg)
Obstetric indications
Coma in Pregnancy
Definition
• Coma is the absence of consciousness. • This state of
unarousable unconsciousness includes the failure of
eye opening to stimulation, a motor response no
better than simple withdrawal-type movements, and
a verbal response no better than simple vocalisation
of non-word sounds
Step-by-step diagnostic approach
• History
• Symptoms of herniation syndromes
• Period of delirium
• Duration of unconsciousness
• Prodromal symptoms
• Presence of convulsions
• Incontinence
• Vision disturbances
• Significant past medical history
Focused general examination
• Blood pressure
• Pulse oximetry
• Core temperature
• Skin-Jaundice, Pallor, cyanosis, Petechial bleeding
• Head and Neck
Coma scoring scales
• Glasgow Coma Scale (GCS)-Commonly used to grade
the severity of the impairment of consciousness
• Initially designed to assess trauma patients in the
emergency department, but it is commonly used to
track the progress or worsening of intensive care unit
(ICU) patients
• Better scales for documenting and following the
depth of coma in ICU patients:
• The Reaction Level Scale
• The FOUR scoring system.[The FOUR Score] These
are more suitable for patients who are intubated,
• have more categories or levels, and include more
aspects of the neurological examination
Glassgow coma scale
FOUR SCORING SYSTEM
Pregnant women may go into coma for
the same reasons that face the general
population, but also encounter conditions
unique to or more common in this state
- Gestational hypertension, eclampsia,
and HELLP
- Pregnancy relatedorgan failures
including acute renal, hepatic, or
pulmonary failure
- Vascular risks include cerebral venous
sinus thrombosis and pituitary apoplexy
COMA –WHEN AND HOW
COMA –WHEN AND HOW
The considerations in coma treatment are generally
similar to those facing patients who are not pregnant.
Coma represents such a dire state that even concerns
such as radiation exposure are usually outweighed by
the need for maternal diagnosis and management
No investigations are categorically excluded (eg,
cerebral angiogram, spiral computed tomography [CT],
or even brain biopsy), because with the prospect of
potentially treatable causes, a mother’s life is accorded
priority.
Etiology
 Etiology similar to other causes of young
stroke- Cardioembolic common
 Physiologic and hemodynamic changes that
occur --state of relative hypercoaguability,
Increased cardiac burden, and altered vascular
tone
 Preeclampsia is associated with a 4-fold
increase in stroke during pregnancy
 Peripartum Cardiomyopathy , Post partum
cerebral angiopathy
Diagnosis
Initial study with a non-contrast head
computerized tomography (CT) with
appropriate fetal shielding or an
magnetic resonance imaging (MRI) of
the brain
Transthoracic or transesophageal
echocardiogram to evaluate for PFO
and the possible presence of an
intracardiac thrombus
hypercoaguability panel is often
performed - results will need to be
repeated several weeks following
delivery
Genetic testing for factor V Leiden and
prothrombin gene mutation would not
be altered by pregnancy
Treatment
TPA - pregnant patients were excluded from tPA
clinical trials and there has been no systematic study
Concerns regarding the risks of tPA on the pregnant
patient and fetus (eg, uterine hemorrhage, placental
abruption, abortion, preterm delivery) have been
raised
that maternal mortality (1%), fetal loss (6%), and
preterm delivery (6%) are all low
Low-dose aspirin for secondary prevention is felt to
be safe during pregnancy
unfractionated or low-molecular weight heparin as these
do not cross the placenta and confer no risk of
teratogenicity or fetal hemorrhage
Defined as an unexplained cardiac
failure occurring during the last month
of pregnancy to the first sixth
postpartum month.
viral and autoimmune causes of
cardiomyopathy have been invoked
Coma may occur from global
cerebral hypoperfusion or by strokes
Peripartum Cardiomyopathy-
Amniotic Fluid Embolism
AFE occurs when amniotic fluid
enters uterine veins and is forced into
the maternal circulation, causing
hemodynamic collapse, disseminated
intravascular coagulopathy (DIC),focal
cerebral hypoperfusion, thrombosis or
hemorrhage,
Hemorrhagic stroke
 Occurs primarily in late pregnancy and in the
puerperium
 Intracerebral hemorrhage has a higher
maternal mortality rate -5% to 12% of overall
maternal mortality during pregnancy
 Primarily associated with preeclampsia /
eclampsia, arteriovenous malformations, and
cerebral aneurysm rupture
 Pathogenesis - increased blood volume, rising
blood pressure, and changes in vascular tone.
 physical stress of labor and delivery may
contribute to rupture risk
 Initial evaluation should include
a noncontrast head CT which will
identify a subarachnoid (often
aneurysmal) or lobar (often AVM)
hemorrhage
Angiographic imaging in an
attempt to identify the source of
the hemorrhage
Cerebral Venous Thrombosis
 CVT represents ≈0.5% to 1% of all
strokes.
 Risk factors are usually divided into
acquired risks (eg, surgery, trauma,
pregnancy, puerperium, antiphospholipid
syndrome, cancer, exogenous hormones)
and genetic risks (inherited thrombophilia).
 Pregnancy and Puerperium-
 Most pregnancy-related CVT occurs in the
third trimester or puerperium.
Clinical Diagnosis of CVT
 headache in 82%,
 papilledema in 56%,
 focal deficits in 42%,
 seizures in 39%
 coma in 31%.
Location of the thrombosis
The superior sagittal sinus is most
commonly -headache, increased ICT, and
papilledema
motor deficit, sometimes with seizures
Investigations
Routine blood studies consisting of a
complete blood count, chemistry panel,
prothrombin time, and activated partial
thromboplastin time should be performed
Treatment
 Treatment of CVT in the nonpregnant
population generally involves
anticoagulation with warfarin
 Unfractionated heparin or low-
molecular weight heparin can be
utilized in pregnancy either as a bridge
to warfarin therapy or as a stand-alone
treatment
Stroke with Eclampsia
 Most common causes of both
ischemic and hemorrhagic stroke in
pregnancy.
 The most frequent cerebrovascular
disturbance associated with eclampsia
is a reversible encephalopathy.
 Preeclampsia/eclampsiacommonly
associated with ischemic stroke of
arterial origin [36 percent]) ,
Intracerebralhemorrhage [55 percent])
Prognosis
 Postpartum eclampsia has a worse
prognosis, often with adult respiratory
distress syndrome (ARDS) and DIC
 Neurological complications more in
postpartum
 Preclampsia increases risk of stroke
over 42 days postpartum
Management
Investigations-
Platelet count and morphology, CBC
PT, aPTT •Uric acid, creatinin,
electrolytes for renal function
Serum uric acid –useful early and for
progression
Hepatic enzymes (AST,ALT,GGT)&
bilirubin
Imaging
•Cerebral imaging is not necessary for
the diagnosis and management of
most women with eclampsia.
•Cerebral imaging findings in
eclampsiaare similar to those found in
patients with hypertensive
encephalopathy
Posterior Reversible
Encephalopathy Syndrome
 Is a clinical radiologic syndrome of
heterogeneous etiologies that are
grouped together because of similar
findings on neuroimaging studies
 May occur in the setting of
preeclampsia due to impaired cerebral
autoregulation from endothelial
damage
 Most common clinical manifestations of
PRES include headaches, confusion,
seizures, and visual changes.
 Confusion is common and may progress
to more significant degrees of altered
awareness
 Seizures may start focally but often
generalize
 More severe cases can result in lasting
neurological morbidity or mortality due to
ischemic stroke or hemorrhage
Findings in
PRES
Cerebral imaging is indicated :-
Focal neurologic deficits
Prolonged coma
Atypical presentation for eclampsia:
Onset before 20 weeks of gestation
or
More than 48 hours after delivery
Eclampsia refractory to adequate
mgso4 therapy
Posterior Reversible
Encephalopathy Syndrome
 Treatment of PRES in the pregnant
patient mirrors that of eclampsia
 Magnesium sulfate is often utilized for
seizure control
 As with eclampsia, hypertension
management is generally achieved
with hydralazine or labetolol
Take Home Message
19/10/2014 38

More Related Content

Similar to coma and convulsions in pregnancy.ppt

Recurrent convulsions in pregnancy 2
Recurrent convulsions in pregnancy 2Recurrent convulsions in pregnancy 2
Recurrent convulsions in pregnancy 2fatimausmani
 
Hypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmadHypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmadAyub Medical College
 
Hypertension in pregnancy
Hypertension in pregnancyHypertension in pregnancy
Hypertension in pregnancyMini Sood
 
Neonatal-Seizures diagnosis and management
Neonatal-Seizures diagnosis and managementNeonatal-Seizures diagnosis and management
Neonatal-Seizures diagnosis and managementFelixBoamah3
 
Figeroa pih
Figeroa   pihFigeroa   pih
Figeroa pihfelling
 
Preeclampsia n eclamsia moumita
Preeclampsia n eclamsia moumitaPreeclampsia n eclamsia moumita
Preeclampsia n eclamsia moumitaMOUMITA MANNA
 
Hypertensive disorders in pregnancy
Hypertensive disorders in pregnancyHypertensive disorders in pregnancy
Hypertensive disorders in pregnancysnigdhanaskar1
 
Eclampsia – neurological aspects
Eclampsia –           neurological aspectsEclampsia –           neurological aspects
Eclampsia – neurological aspectsNeurologyKota
 
2_2019_07_14!01_14_14_PM.ppt
2_2019_07_14!01_14_14_PM.ppt2_2019_07_14!01_14_14_PM.ppt
2_2019_07_14!01_14_14_PM.pptdeepikaagarwal68
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxDebdattaMandal5
 
Severe hyperemesis gravidarum of pregnancy
Severe hyperemesis gravidarum of pregnancySevere hyperemesis gravidarum of pregnancy
Severe hyperemesis gravidarum of pregnancyAlkaPandey24
 
Hypertensive disorders in Pregnancy
Hypertensive disorders in PregnancyHypertensive disorders in Pregnancy
Hypertensive disorders in PregnancyHanifullah Khan
 
04_Modern problems of pregnancy induced hypertension-2019.pptx
04_Modern problems of pregnancy induced hypertension-2019.pptx04_Modern problems of pregnancy induced hypertension-2019.pptx
04_Modern problems of pregnancy induced hypertension-2019.pptxUgo161BB
 
Anesthesia ForPregnancy induced hypertension
Anesthesia ForPregnancy induced hypertension Anesthesia ForPregnancy induced hypertension
Anesthesia ForPregnancy induced hypertension krishna dhakal
 
CME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptxCME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptxyogeswary7
 

Similar to coma and convulsions in pregnancy.ppt (20)

Recurrent convulsions in pregnancy 2
Recurrent convulsions in pregnancy 2Recurrent convulsions in pregnancy 2
Recurrent convulsions in pregnancy 2
 
Hypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmadHypertension in pregnancy By Dr ahmad
Hypertension in pregnancy By Dr ahmad
 
Hypertension in pregnancy
Hypertension in pregnancyHypertension in pregnancy
Hypertension in pregnancy
 
Neonatal-Seizures diagnosis and management
Neonatal-Seizures diagnosis and managementNeonatal-Seizures diagnosis and management
Neonatal-Seizures diagnosis and management
 
Figeroa pih
Figeroa   pihFigeroa   pih
Figeroa pih
 
Eclampsia final
Eclampsia finalEclampsia final
Eclampsia final
 
Preeclampsia n eclamsia moumita
Preeclampsia n eclamsia moumitaPreeclampsia n eclamsia moumita
Preeclampsia n eclamsia moumita
 
Hypertensive disorders in pregnancy
Hypertensive disorders in pregnancyHypertensive disorders in pregnancy
Hypertensive disorders in pregnancy
 
Eclampsia – neurological aspects
Eclampsia –           neurological aspectsEclampsia –           neurological aspects
Eclampsia – neurological aspects
 
2_2019_07_14!01_14_14_PM.ppt
2_2019_07_14!01_14_14_PM.ppt2_2019_07_14!01_14_14_PM.ppt
2_2019_07_14!01_14_14_PM.ppt
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptx
 
Neonatal emergencies
Neonatal emergenciesNeonatal emergencies
Neonatal emergencies
 
1. Status Epilepticus-Nutshell.pptx
1. Status Epilepticus-Nutshell.pptx1. Status Epilepticus-Nutshell.pptx
1. Status Epilepticus-Nutshell.pptx
 
Severe hyperemesis gravidarum of pregnancy
Severe hyperemesis gravidarum of pregnancySevere hyperemesis gravidarum of pregnancy
Severe hyperemesis gravidarum of pregnancy
 
Hypertensive disorders in Pregnancy
Hypertensive disorders in PregnancyHypertensive disorders in Pregnancy
Hypertensive disorders in Pregnancy
 
04_Modern problems of pregnancy induced hypertension-2019.pptx
04_Modern problems of pregnancy induced hypertension-2019.pptx04_Modern problems of pregnancy induced hypertension-2019.pptx
04_Modern problems of pregnancy induced hypertension-2019.pptx
 
Eclampsia
EclampsiaEclampsia
Eclampsia
 
Anesthesia ForPregnancy induced hypertension
Anesthesia ForPregnancy induced hypertension Anesthesia ForPregnancy induced hypertension
Anesthesia ForPregnancy induced hypertension
 
Farshidmokhberi
FarshidmokhberiFarshidmokhberi
Farshidmokhberi
 
CME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptxCME Hypertension in Pregnancy yoges edited.pptx
CME Hypertension in Pregnancy yoges edited.pptx
 

More from ParulSinha25

04._Malpresentations era lectures.pptx
04._Malpresentations era lectures.pptx04._Malpresentations era lectures.pptx
04._Malpresentations era lectures.pptxParulSinha25
 
polyhydramnios lecture era.pptx
polyhydramnios lecture era.pptxpolyhydramnios lecture era.pptx
polyhydramnios lecture era.pptxParulSinha25
 
secondary amenorrhoea lectures.ppt
secondary amenorrhoea lectures.pptsecondary amenorrhoea lectures.ppt
secondary amenorrhoea lectures.pptParulSinha25
 
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptx
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptxD1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptx
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptxParulSinha25
 
Birth_Canal_Injuries_final_lecture.pptx
Birth_Canal_Injuries_final_lecture.pptxBirth_Canal_Injuries_final_lecture.pptx
Birth_Canal_Injuries_final_lecture.pptxParulSinha25
 

More from ParulSinha25 (7)

GTN (1).ppt
GTN (1).pptGTN (1).ppt
GTN (1).ppt
 
04._Malpresentations era lectures.pptx
04._Malpresentations era lectures.pptx04._Malpresentations era lectures.pptx
04._Malpresentations era lectures.pptx
 
polyhydramnios lecture era.pptx
polyhydramnios lecture era.pptxpolyhydramnios lecture era.pptx
polyhydramnios lecture era.pptx
 
secondary amenorrhoea lectures.ppt
secondary amenorrhoea lectures.pptsecondary amenorrhoea lectures.ppt
secondary amenorrhoea lectures.ppt
 
CIN.ppt
CIN.pptCIN.ppt
CIN.ppt
 
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptx
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptxD1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptx
D1 Final Group Dynamics & Team BuildingBasic MCI Coursr.pptx
 
Birth_Canal_Injuries_final_lecture.pptx
Birth_Canal_Injuries_final_lecture.pptxBirth_Canal_Injuries_final_lecture.pptx
Birth_Canal_Injuries_final_lecture.pptx
 

Recently uploaded

BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.PraveenaKalaiselvan1
 
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfSELF-EXPLANATORY
 
Harmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms PresentationHarmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms Presentationtahreemzahra82
 
Pests of soyabean_Binomics_IdentificationDr.UPR.pdf
Pests of soyabean_Binomics_IdentificationDr.UPR.pdfPests of soyabean_Binomics_IdentificationDr.UPR.pdf
Pests of soyabean_Binomics_IdentificationDr.UPR.pdfPirithiRaju
 
Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Nistarini College, Purulia (W.B) India
 
Transposable elements in prokaryotes.ppt
Transposable elements in prokaryotes.pptTransposable elements in prokaryotes.ppt
Transposable elements in prokaryotes.pptArshadWarsi13
 
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxSTOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxMurugaveni B
 
Environmental Biotechnology Topic:- Microbial Biosensor
Environmental Biotechnology Topic:- Microbial BiosensorEnvironmental Biotechnology Topic:- Microbial Biosensor
Environmental Biotechnology Topic:- Microbial Biosensorsonawaneprad
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real timeSatoshi NAKAHIRA
 
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdf
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdfPests of Blackgram, greengram, cowpea_Dr.UPR.pdf
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdfPirithiRaju
 
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)User Guide: Pulsar™ Weather Station (Columbia Weather Systems)
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)Columbia Weather Systems
 
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxAnalytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxSwapnil Therkar
 
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuine
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 GenuineCall Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuine
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuinethapagita
 
Microteaching on terms used in filtration .Pharmaceutical Engineering
Microteaching on terms used in filtration .Pharmaceutical EngineeringMicroteaching on terms used in filtration .Pharmaceutical Engineering
Microteaching on terms used in filtration .Pharmaceutical EngineeringPrajakta Shinde
 
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptx
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptxLIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptx
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptxmalonesandreagweneth
 
Speech, hearing, noise, intelligibility.pptx
Speech, hearing, noise, intelligibility.pptxSpeech, hearing, noise, intelligibility.pptx
Speech, hearing, noise, intelligibility.pptxpriyankatabhane
 
preservation, maintanence and improvement of industrial organism.pptx
preservation, maintanence and improvement of industrial organism.pptxpreservation, maintanence and improvement of industrial organism.pptx
preservation, maintanence and improvement of industrial organism.pptxnoordubaliya2003
 
Solution chemistry, Moral and Normal solutions
Solution chemistry, Moral and Normal solutionsSolution chemistry, Moral and Normal solutions
Solution chemistry, Moral and Normal solutionsHajira Mahmood
 
Citronella presentation SlideShare mani upadhyay
Citronella presentation SlideShare mani upadhyayCitronella presentation SlideShare mani upadhyay
Citronella presentation SlideShare mani upadhyayupadhyaymani499
 
Topic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxTopic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxJorenAcuavera1
 

Recently uploaded (20)

BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
BIOETHICS IN RECOMBINANT DNA TECHNOLOGY.
 
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdfBehavioral Disorder: Schizophrenia & it's Case Study.pdf
Behavioral Disorder: Schizophrenia & it's Case Study.pdf
 
Harmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms PresentationHarmful and Useful Microorganisms Presentation
Harmful and Useful Microorganisms Presentation
 
Pests of soyabean_Binomics_IdentificationDr.UPR.pdf
Pests of soyabean_Binomics_IdentificationDr.UPR.pdfPests of soyabean_Binomics_IdentificationDr.UPR.pdf
Pests of soyabean_Binomics_IdentificationDr.UPR.pdf
 
Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...
 
Transposable elements in prokaryotes.ppt
Transposable elements in prokaryotes.pptTransposable elements in prokaryotes.ppt
Transposable elements in prokaryotes.ppt
 
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptxSTOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
STOPPED FLOW METHOD & APPLICATION MURUGAVENI B.pptx
 
Environmental Biotechnology Topic:- Microbial Biosensor
Environmental Biotechnology Topic:- Microbial BiosensorEnvironmental Biotechnology Topic:- Microbial Biosensor
Environmental Biotechnology Topic:- Microbial Biosensor
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real time
 
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdf
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdfPests of Blackgram, greengram, cowpea_Dr.UPR.pdf
Pests of Blackgram, greengram, cowpea_Dr.UPR.pdf
 
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)User Guide: Pulsar™ Weather Station (Columbia Weather Systems)
User Guide: Pulsar™ Weather Station (Columbia Weather Systems)
 
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptxAnalytical Profile of Coleus Forskohlii | Forskolin .pptx
Analytical Profile of Coleus Forskohlii | Forskolin .pptx
 
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuine
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 GenuineCall Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuine
Call Girls in Majnu Ka Tilla Delhi 🔝9711014705🔝 Genuine
 
Microteaching on terms used in filtration .Pharmaceutical Engineering
Microteaching on terms used in filtration .Pharmaceutical EngineeringMicroteaching on terms used in filtration .Pharmaceutical Engineering
Microteaching on terms used in filtration .Pharmaceutical Engineering
 
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptx
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptxLIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptx
LIGHT-PHENOMENA-BY-CABUALDIONALDOPANOGANCADIENTE-CONDEZA (1).pptx
 
Speech, hearing, noise, intelligibility.pptx
Speech, hearing, noise, intelligibility.pptxSpeech, hearing, noise, intelligibility.pptx
Speech, hearing, noise, intelligibility.pptx
 
preservation, maintanence and improvement of industrial organism.pptx
preservation, maintanence and improvement of industrial organism.pptxpreservation, maintanence and improvement of industrial organism.pptx
preservation, maintanence and improvement of industrial organism.pptx
 
Solution chemistry, Moral and Normal solutions
Solution chemistry, Moral and Normal solutionsSolution chemistry, Moral and Normal solutions
Solution chemistry, Moral and Normal solutions
 
Citronella presentation SlideShare mani upadhyay
Citronella presentation SlideShare mani upadhyayCitronella presentation SlideShare mani upadhyay
Citronella presentation SlideShare mani upadhyay
 
Topic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptxTopic 9- General Principles of International Law.pptx
Topic 9- General Principles of International Law.pptx
 

coma and convulsions in pregnancy.ppt

  • 1. PREGNANCY WITH CONVULSIONS AND COMA- RARE BUT DREADED DISASTERS
  • 2. Convulsions in pregnancy Convulsions due to pregnancy Eclampsia Convulsions aggravated by Pregnancy Epilepsy
  • 3. Convulsions in pregnancy Convulsions not Directly related to pregnancy Infections Meningitis Encephalitis Cerebral Malaria Cerebral Absces Febrile convulsions Cerebrovascular Accidents Venous Thrombosis Infarction Haemorrhage Metabolic/Electolyte imbalance Hypoglycemia Hyperglycemia Hyponatremia Hypocalcemia Trauma Tetany Drug Withdrawal Cocaine Alcohol Psychiatric disorders
  • 4. ECLAMPSIA New-onset convulsionsafter 20wks of pregnancy in a patient with Preeclampsia (PIH) with no coincidental neurologic disease, is called Eclampsia.
  • 5. Eclampsia The incidence of eclampsia in the developed countries is 1:2000 deliveries. while in developing countries estimate vary widely, from 1 in 100 to 1 in 1700 deliveries . ANTEPARTUM (50%) INTRAPARTUM (30%). POSTPARTUM (20%) within 48hrs-upto 7days. INTERCURRENT (Rare) – Pt becomes conscious after recovery from convulsion and pregnancy continues beyond 48hrs.
  • 6. Convulsions in Pregnancy Differential Diagnosis Eclampsia History Occurs after 20wks of preg H/o PIH in this Pregnancy Prev H/o Eclampsia +/- H/o Tonic Clonic convulsion Clinical Exam H/o Hypertension, Proteinuria,Edema,Oliguri a,p ulmonary Edema Epilepsy Occur anytime during preg H/o Prev Epileptic fits Fits may be Recurrent Fits Generalised/Focal No H/o Hypertension,Proteinuria, Edema
  • 7. Convulsion in Pregnancy Differential Diagnosis Investigations Eclampsia Complete bloodcount Haematocrit Plateletcount  Coagulation profile  Serum creatinine Serum uric acid Liver function tests Complete urine examination Fundoscopy Epilepsy EEG Cerebral Imaging (MRI)
  • 8. Maternal Complications of Eclampsia Injuries –Tongue bite Pulmonary Edema. Aspiration Pneumonia(2%- 5%) Long Term Cardiovascular Morbidity Abruptio- Placentae (1%-4%) Disseminated Coagulopathy. HELLP Syndrome (3-4%) Acute Renal Failure (1%-5%) Liver Failure OR Haemorrhage (<1%) Cerebral haemorrhage Postpartum collapse Blindness Death (Rare)
  • 9. Complications  IUGR(10-25%) Hypoxia- Neurologic Injury (<1%) Perinatal Death (1%-2%) Long Term Cardiovascular Morbidity Associated with Low Birth Weight
  • 10. AIMS OF MANAGEMENT OF ECLAMPSIA Control convulsions, prevent cerebro-vascular accident and COMA Stabilise blood pressure Optimise patient Deliver fetus 19/10/2014 11
  • 11. Management of eclampsia Teamapproach O&G specialist Anesthesiologist  Paediatrician Physician Nursing Staff Blood bank personnel
  • 12. GENERAL MANAGEMENT OF ECLAMPSIA position patient to herside in railed cot Mouth gag placed between theteeth clearairway secretions maintain oxygenation 15 LIT/ MIN set up intravenousaccess Put self retaining catheter monitor vital signs - BP, PR, respiration1/2hrly if diastolic BP > 110mmHg, considerantihypertensive monitor fetal heart rate forgestations > 28 weeks Antibiotic 13
  • 14. MgSO4 Mechanism ofaction Slowed neuromuscular conduction & decreased CNS irritability Cerebral vasodilatation Increased production of endothelial prostacycline and inhibition of platelet activation Protection of endothelial cells from injury mediated by free radicals Dilatation of uterine arteries
  • 15. MgSo4 as anticonvulsant Prichard’s regimen (IM) Loading Dose- 4gm (20%) slow IV over 3-5mt f/b 10gm (50%) deep IM (5gm in each buttock) Maintenance Dose- 5gm (50%) IM 4hrly in alternate buttock Zuspan regimen (IV) Loading Dose-4-6gm slow IV in 100ml 5% Dextrose over 15-20 mt F/b 5gm IV in 5%Dextrose(1gm/hr IV infusion)
  • 16. Monitoring of patient on magnesium sulphate Therapeutic levels (if available)  Serum magnesium levels between 4.0-7.0 mEq/L Patellar reflex Present (Lost at serum Mg Levels of 8 – 10 mEq/L Urine Output >30 ml/ hr Every hour Respiratory rate > 12/min every 15 mins Respiratory depression (serum Mg level >10 mEq/L) Respiratory arrest (serum Mg level > 12 mEq/L) 19/10/2014 17
  • 17.  Managing Magnesium Toxicity  Respiratory depression  Stop magnesiumtherapy  Oxygen  IVcalciumgluconate 10% 10ml IV slow bolus  Maintainairway  Respiratory arrest  Stop magnesiumtherapy  IVcalciumgluconate 10% 10 ml IV slow bolus  Tracheal Intubation andventilation 19/10/2014 18
  • 18. Effects of Mg sulphate on thenewborn MgSO4 crosses the placentafreely Minimal side effects if maternal serum levels are maintained Hyporeflexia and Respiratory depression Lethargy 19
  • 19. - Anticonvulsant therapy Diazepam  Useful for status seizures  dosage – 10 -20 mg iv at a rate of 5 mg per min  may be repeated at 10 to 15 minute intervals  Maintainence – 40mg in 500ml of 5% Dextrose IV infusion,to keep patient sedated Side effects - loss of consciousness, hypotension, respiratory depression Caution - may increase risk of aspiration causes prolonged depression of the neonate
  • 20. Phenytoin  Centrally acting anticonvulsant Dose ( with ECG monitoring ) 10mg/Kg I/V (not more than50mg/mt) F/b 5mg/Kg I/V after 2hr 12 hr. — 500mg I/V 200mg 8hrly. X 5 days SE- Hypotension, Cardiac dysrhythmia & Phlebitis
  • 21. Fluid replacement Should not exceed 1-2 ml/kg/hour or 85 ml/hour whichever is lower Crystalloid Solution (RL) Total Fluid =24hr urine +1000ml Maintain a urine output of more than 30 ml/hour CVP should not exceed 7 cm of H2O When patient is taking oral fluids, the amount taken should be subtracted from the amount infused 22
  • 22. Anti hypertensive management Objective is to prevent maternal cerebrovascular accidents Hydralazine  5mg -10mg I/V at 15 – 20 mts. Interval till control is achieved. Maximum dose 15mg – 20mg Labetelol  Start with 200mg/100ml IV at 20mg/hr. I/v. Double the dose every 30 min. till control is achieved or a dose of 160mg/hr. is reached  Nifedipine  5mmg – 10mg S/L every 15 – 30 minutes until BP is contolled A maximum 180mg can be used in a day
  • 23. Treatment of complications of Eclampsia If pulmonary oedema develops, give intravenous Frusemide 40mg, oxygen and manage patient in the ICU If oliguria develops or when urine output is less than 30ml/hour for 4 hours – challenge with 200 mls of crystalloid over 5 minutes . Evaluate over a 4 hour period If oliguria persists despite a CVP of between 7 – 10 cm H2O – refer to Nephrologist for further management. Hyperpyrexia- Cold sponging , Antipyretics Heart failure-O2 inhalation, IV Lasix, & Digitalis 24
  • 24. Obstetrical management of eclampsia treatment The Definitive Is Delivery 19/10/2014 25
  • 25. Indications of LSCS IN Eclampsia Uncontrolled fits in spite oftherapy Poor prospects for vaginalDelivery Worsening maternal diseaseprocess Uncontrolled hypertension (>180/120mm Hg) Obstetric indications
  • 27. Definition • Coma is the absence of consciousness. • This state of unarousable unconsciousness includes the failure of eye opening to stimulation, a motor response no better than simple withdrawal-type movements, and a verbal response no better than simple vocalisation of non-word sounds
  • 28. Step-by-step diagnostic approach • History • Symptoms of herniation syndromes • Period of delirium • Duration of unconsciousness • Prodromal symptoms • Presence of convulsions • Incontinence • Vision disturbances • Significant past medical history
  • 29. Focused general examination • Blood pressure • Pulse oximetry • Core temperature • Skin-Jaundice, Pallor, cyanosis, Petechial bleeding • Head and Neck
  • 30. Coma scoring scales • Glasgow Coma Scale (GCS)-Commonly used to grade the severity of the impairment of consciousness • Initially designed to assess trauma patients in the emergency department, but it is commonly used to track the progress or worsening of intensive care unit (ICU) patients • Better scales for documenting and following the depth of coma in ICU patients: • The Reaction Level Scale • The FOUR scoring system.[The FOUR Score] These are more suitable for patients who are intubated, • have more categories or levels, and include more aspects of the neurological examination
  • 33. Pregnant women may go into coma for the same reasons that face the general population, but also encounter conditions unique to or more common in this state - Gestational hypertension, eclampsia, and HELLP - Pregnancy relatedorgan failures including acute renal, hepatic, or pulmonary failure - Vascular risks include cerebral venous sinus thrombosis and pituitary apoplexy COMA –WHEN AND HOW
  • 34. COMA –WHEN AND HOW The considerations in coma treatment are generally similar to those facing patients who are not pregnant. Coma represents such a dire state that even concerns such as radiation exposure are usually outweighed by the need for maternal diagnosis and management No investigations are categorically excluded (eg, cerebral angiogram, spiral computed tomography [CT], or even brain biopsy), because with the prospect of potentially treatable causes, a mother’s life is accorded priority.
  • 35. Etiology  Etiology similar to other causes of young stroke- Cardioembolic common  Physiologic and hemodynamic changes that occur --state of relative hypercoaguability, Increased cardiac burden, and altered vascular tone  Preeclampsia is associated with a 4-fold increase in stroke during pregnancy  Peripartum Cardiomyopathy , Post partum cerebral angiopathy
  • 36. Diagnosis Initial study with a non-contrast head computerized tomography (CT) with appropriate fetal shielding or an magnetic resonance imaging (MRI) of the brain
  • 37. Transthoracic or transesophageal echocardiogram to evaluate for PFO and the possible presence of an intracardiac thrombus hypercoaguability panel is often performed - results will need to be repeated several weeks following delivery Genetic testing for factor V Leiden and prothrombin gene mutation would not be altered by pregnancy
  • 38. Treatment TPA - pregnant patients were excluded from tPA clinical trials and there has been no systematic study Concerns regarding the risks of tPA on the pregnant patient and fetus (eg, uterine hemorrhage, placental abruption, abortion, preterm delivery) have been raised that maternal mortality (1%), fetal loss (6%), and preterm delivery (6%) are all low Low-dose aspirin for secondary prevention is felt to be safe during pregnancy unfractionated or low-molecular weight heparin as these do not cross the placenta and confer no risk of teratogenicity or fetal hemorrhage
  • 39. Defined as an unexplained cardiac failure occurring during the last month of pregnancy to the first sixth postpartum month. viral and autoimmune causes of cardiomyopathy have been invoked Coma may occur from global cerebral hypoperfusion or by strokes Peripartum Cardiomyopathy-
  • 40. Amniotic Fluid Embolism AFE occurs when amniotic fluid enters uterine veins and is forced into the maternal circulation, causing hemodynamic collapse, disseminated intravascular coagulopathy (DIC),focal cerebral hypoperfusion, thrombosis or hemorrhage,
  • 41. Hemorrhagic stroke  Occurs primarily in late pregnancy and in the puerperium  Intracerebral hemorrhage has a higher maternal mortality rate -5% to 12% of overall maternal mortality during pregnancy  Primarily associated with preeclampsia / eclampsia, arteriovenous malformations, and cerebral aneurysm rupture  Pathogenesis - increased blood volume, rising blood pressure, and changes in vascular tone.  physical stress of labor and delivery may contribute to rupture risk
  • 42.  Initial evaluation should include a noncontrast head CT which will identify a subarachnoid (often aneurysmal) or lobar (often AVM) hemorrhage Angiographic imaging in an attempt to identify the source of the hemorrhage
  • 43. Cerebral Venous Thrombosis  CVT represents ≈0.5% to 1% of all strokes.  Risk factors are usually divided into acquired risks (eg, surgery, trauma, pregnancy, puerperium, antiphospholipid syndrome, cancer, exogenous hormones) and genetic risks (inherited thrombophilia).  Pregnancy and Puerperium-  Most pregnancy-related CVT occurs in the third trimester or puerperium.
  • 44. Clinical Diagnosis of CVT  headache in 82%,  papilledema in 56%,  focal deficits in 42%,  seizures in 39%  coma in 31%. Location of the thrombosis The superior sagittal sinus is most commonly -headache, increased ICT, and papilledema motor deficit, sometimes with seizures
  • 45. Investigations Routine blood studies consisting of a complete blood count, chemistry panel, prothrombin time, and activated partial thromboplastin time should be performed
  • 46. Treatment  Treatment of CVT in the nonpregnant population generally involves anticoagulation with warfarin  Unfractionated heparin or low- molecular weight heparin can be utilized in pregnancy either as a bridge to warfarin therapy or as a stand-alone treatment
  • 47. Stroke with Eclampsia  Most common causes of both ischemic and hemorrhagic stroke in pregnancy.  The most frequent cerebrovascular disturbance associated with eclampsia is a reversible encephalopathy.  Preeclampsia/eclampsiacommonly associated with ischemic stroke of arterial origin [36 percent]) , Intracerebralhemorrhage [55 percent])
  • 48. Prognosis  Postpartum eclampsia has a worse prognosis, often with adult respiratory distress syndrome (ARDS) and DIC  Neurological complications more in postpartum  Preclampsia increases risk of stroke over 42 days postpartum
  • 49. Management Investigations- Platelet count and morphology, CBC PT, aPTT •Uric acid, creatinin, electrolytes for renal function Serum uric acid –useful early and for progression Hepatic enzymes (AST,ALT,GGT)& bilirubin
  • 50. Imaging •Cerebral imaging is not necessary for the diagnosis and management of most women with eclampsia. •Cerebral imaging findings in eclampsiaare similar to those found in patients with hypertensive encephalopathy
  • 51. Posterior Reversible Encephalopathy Syndrome  Is a clinical radiologic syndrome of heterogeneous etiologies that are grouped together because of similar findings on neuroimaging studies  May occur in the setting of preeclampsia due to impaired cerebral autoregulation from endothelial damage
  • 52.  Most common clinical manifestations of PRES include headaches, confusion, seizures, and visual changes.  Confusion is common and may progress to more significant degrees of altered awareness  Seizures may start focally but often generalize  More severe cases can result in lasting neurological morbidity or mortality due to ischemic stroke or hemorrhage
  • 54. Cerebral imaging is indicated :- Focal neurologic deficits Prolonged coma Atypical presentation for eclampsia: Onset before 20 weeks of gestation or More than 48 hours after delivery Eclampsia refractory to adequate mgso4 therapy Posterior Reversible Encephalopathy Syndrome
  • 55.  Treatment of PRES in the pregnant patient mirrors that of eclampsia  Magnesium sulfate is often utilized for seizure control  As with eclampsia, hypertension management is generally achieved with hydralazine or labetolol